Management strategies in benign eyelid lesions
OphthaTherapy. Therapies in Ophthalmology · 2024
DOI: 10.24292/01.ot.031624 ↗Kurz gefasst
Fachartikel in der Zeitschrift OphthaTherapy. Therapies in Ophthalmology, 2024. Verfasst von Anna Jagielak-Grab und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Eyelid tumors are a common discovery during an ophthalmological or dermatological examination. According to available knowledge, they constitute about 5–10% of skin tumors. The majority of them are benign and can be classified as inflammatory, infectious, traumatic or neoplastic lesions. Depending on the lesion type, there are different approaches to management that include: observation, topical application of steroids or antibiotics, injection of steroids, application of warm compresses, biopsy, excision, curettage, various types of laser therapy or plasma-based therapies, cryosurgery and electrocautery. Malignant eyelid tumors are not rare, therefore, an accurate diagnosis is crucial to provide best suited type of treatment. In many cases, an experienced physician is able to distinguish a benign lesion basing on clinical examination, however, it is often difficult to differentiate benign tumors from malignant and premalignant lesions. In case of any uncertainty, a biopsy followed by histopathological examination should always be taken into consideration.
Zitieren
APA
Jagielak-Grab, A., Białas, D., Szabelska, P., & Różycki, R. (2024). Management strategies in benign eyelid lesions. OphthaTherapy. Therapies in Ophthalmology. https://doi.org/10.24292/01.ot.031624
Vancouver
Jagielak-Grab A, Białas D, Szabelska P, Różycki R. Management strategies in benign eyelid lesions. OphthaTherapy. Therapies in Ophthalmology. 2024. doi:10.24292/01.ot.031624
BibTeX
@article{JagielakGrab2024,
author = {Jagielak-Grab, Anna and Białas, Dominika and Szabelska, Paulina and Różycki, Radosław},
title = {Management strategies in benign eyelid lesions},
journal = {OphthaTherapy. Therapies in Ophthalmology},
year = {2024},
doi = {10.24292/01.ot.031624}
}
EUVIMED